Celcuity LLC (CELC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celcuity LLC (CELC) has a cash flow conversion efficiency ratio of -0.383x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.82 Million) by net assets ($116.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celcuity LLC - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Celcuity LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Celcuity LLC balance sheet liabilities for a breakdown of total debt and financial obligations.
Celcuity LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celcuity LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bancolombia S.A
F:BXK
|
0.267x |
|
Hongta Securities Co Ltd
SHG:601236
|
0.053x |
|
Axos Financial Inc
NYSE:AX
|
0.042x |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
0.038x |
|
Linktel Technologies Co. Ltd. A
SHE:301205
|
0.003x |
|
Shanghai Sinyang Semiconductor
SHE:300236
|
0.042x |
|
Boc International China Co Ltd
SHG:601696
|
0.345x |
|
China Vanke Co Ltd Class A
SHE:000002
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Celcuity LLC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Celcuity LLC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Celcuity LLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $115.62 Million | $-83.47 Million | -0.722x | -87.51% |
| 2023-12-31 | $139.77 Million | $-53.81 Million | -0.385x | -43.03% |
| 2022-12-31 | $133.77 Million | $-36.01 Million | -0.269x | +8.94% |
| 2021-12-31 | $68.71 Million | $-20.31 Million | -0.296x | +51.59% |
| 2020-12-31 | $11.70 Million | $-7.15 Million | -0.611x | -96.43% |
| 2019-12-31 | $19.30 Million | $-6.00 Million | -0.311x | -29.68% |
| 2018-12-31 | $25.35 Million | $-6.08 Million | -0.240x | -52.07% |
| 2017-12-31 | $31.39 Million | $-4.95 Million | -0.158x | +69.38% |
| 2016-12-31 | $5.61 Million | $-2.89 Million | -0.515x | -30.48% |
| 2015-12-31 | $5.02 Million | $-1.98 Million | -0.394x | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more